Yes, hyperlipidemia is a modifiable risk factor for cardiovascular disease. Unlike fixed risk factors such as age, sex, and family history, abnormal cholesterol and triglyceride levels can be changed through diet, exercise, medication, or a combination of all three. Every 39 mg/dL reduction in LDL cholesterol lowers the risk of major cardiovascular events by roughly 22%.
What Makes a Risk Factor Modifiable
In cardiovascular medicine, risk factors fall into two categories. Non-modifiable risk factors are things you cannot change: your age, your biological sex, and your genetic makeup. Modifiable risk factors are conditions you can treat, reverse, or manage to lower your chances of heart attack and stroke. High blood pressure, smoking, type 2 diabetes, and hyperlipidemia all fall into the modifiable category.
Hyperlipidemia earns this classification because the core lipid values that define it, including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, all respond to intervention. The degree of improvement varies from person to person, but the direction is consistent: targeted changes bring lipid levels down, and lower lipid levels translate to fewer cardiovascular events.
How Much Lifestyle Changes Can Lower Cholesterol
Diet and exercise alone can reduce blood cholesterol levels by an estimated 5% to 15%, with some people experiencing even larger drops. The most effective dietary strategies involve reducing saturated fat, increasing soluble fiber from sources like oats, beans, and vegetables, and replacing animal fats with unsaturated fats from fish, nuts, and olive oil. Regular aerobic exercise, even moderate activity like brisk walking, helps raise HDL (the protective form of cholesterol) while lowering triglycerides.
For someone whose LDL is mildly elevated, lifestyle changes alone may be enough to bring it into a healthy range. For people with higher starting levels or additional risk factors like diabetes, lifestyle changes remain important but typically need to be paired with medication to reach target levels.
What Medications Can Achieve
When lifestyle changes aren’t sufficient, medications can produce dramatic reductions. High-intensity statins lower LDL cholesterol by approximately 40% to 54%, depending on the specific drug and dose. A second class of medication that blocks cholesterol absorption in the gut is often added on top of a statin for patients who need further lowering. For people at very high risk, injectable medications that target a protein called PCSK9 can reduce LDL by about 52% when used alone.
These treatments also affect other lipid markers. High-intensity statins cut triglycerides by around 22% and raise HDL by about 4%. PCSK9 inhibitors raise HDL by roughly 8%. The 2025 ACC/AHA guidelines now recommend considering treatment intensification when LDL remains above 55 mg/dL in high-risk patients, down from the previous threshold of 70 mg/dL. This reflects growing evidence that lower is better when it comes to LDL.
Triglycerides Are Modifiable Too
The conversation around hyperlipidemia often focuses on LDL, but elevated triglycerides also contribute to cardiovascular risk and respond to treatment. Globally, about 29% of adults have high triglycerides, and 38% have low HDL, both of which independently raise the risk of heart disease.
For years, the evidence on triglyceride-lowering treatments was mixed. Older medications showed clear benefits only in people with both high triglycerides and low HDL. That changed with the REDUCE-IT trial, which found that a purified prescription omega-3 fatty acid reduced cardiovascular events by 25% in high-risk patients with elevated triglycerides who were already on statin therapy. A broader meta-analysis of 24 triglyceride-lowering trials confirmed that reducing triglyceride levels is associated with fewer major cardiovascular events, even after accounting for LDL changes. Multiple major health organizations now recommend this targeted treatment for high-risk patients with persistent triglyceride elevations.
The Genetic Nuance
One complication worth understanding: about 1 in 313 people worldwide has familial hypercholesterolemia, a genetic condition that impairs the body’s ability to clear LDL from the bloodstream. For these individuals, high cholesterol has a non-modifiable root cause. However, the cholesterol levels themselves are still modifiable with treatment. People with familial hypercholesterolemia typically need medication from an early age, and lifestyle changes alone won’t be enough, but their LDL can still be brought down significantly.
Interestingly, the relationship between genetics and cholesterol is less straightforward than it might seem. Research from the Hamburg City Health Study found that only about half of people with a confirmed genetic mutation for familial hypercholesterolemia actually had LDL levels above 190 mg/dL. Nearly a third had levels below 160 mg/dL. At the same time, the vast majority of people with very high LDL carry no genetic mutation at all. This means most cases of hyperlipidemia are driven primarily by modifiable factors like diet, body weight, and physical activity rather than inherited genes.
When Another Condition Is Driving It
Hyperlipidemia sometimes develops as a consequence of another medical condition. Hypothyroidism is one of the most common culprits. When the thyroid is underactive, LDL and total cholesterol tend to rise. Thyroid hormone replacement therapy can improve these lipid levels, and importantly, treating the underlying thyroid problem should come before adding cholesterol-lowering drugs. Starting a statin without addressing hypothyroidism first can increase the risk of muscle-related side effects.
Kidney disease, particularly nephrotic syndrome, is another secondary cause. Chronic kidney disease alters how the body processes fats, leading to elevated cholesterol and triglycerides. Treating the kidney condition and adjusting the diet can improve the lipid profile. In these cases, modifying hyperlipidemia means treating the root cause, not just the numbers on a lab report.
How Often to Check Your Levels
Screening for hyperlipidemia is recommended starting at age 20 as part of a general cardiovascular risk assessment. For adults without known heart disease, a lipid panel every four to six years is the standard interval. Younger adults (men 20 to 45 and women 20 to 55) are generally screened every five years. If you’re on treatment or have risk factors like diabetes or a family history of early heart disease, more frequent testing helps track whether interventions are working and whether adjustments are needed.
The fact that hyperlipidemia responds so reliably to intervention is precisely why screening matters. Catching elevated levels early gives you the widest range of options, from dietary changes alone in mild cases to combination medication regimens for those at highest risk. Unlike your age or your genes, your cholesterol levels are something you can move in the right direction.